.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
India's biotechnology sector has witnessed a massive transformation over the last decade. Specifically, the industry grew from $10 billion to over $195 billion since 2014. Union Minister Dr. Jitendra Singh shared these details during a recent foundation day event in New Delhi. He attributed this success to enabling policies and strong government support. Moreover, the sector recorded an annual growth rate of roughly 18% in the last year alone. Consequently, the bioeconomy now contributes nearly 4.8% to India's national GDP.
Notably, this growth occurred despite global challenges like the COVID-19 pandemic. The minister highlighted that resilience remains a key driver of this progress. India's ability to persist under constraints has defined its innovation strength. Furthermore, the government has prioritized science and technology to build a robust ecosystem. Therefore, India is now on track to become the world’s third-largest economy soon.
The Biotechnology Industry Research Assistance Council (BIRAC) has played a critical role in this journey. Specifically, it has moved beyond random collaborations to a structured, outcome-driven approach. BIRAC identifies the right partners and provides targeted funding for innovators. Additionally, it offers mentorship and incubation support to strengthen industry-academia ties. Currently, over 11,800 biotech startups are powering this expanding ecosystem across the country.
Moreover, BIRAC has facilitated significant investment in deep-tech solutions. The agency now manages substantial funds to support later-stage advanced technology companies. Consequently, many laboratory ideas have successfully transitioned into market-ready solutions. This synergy between research and industry remains essential for long-term sustainability. Notably, the government’s BioE3 policy further strengthens bio-based industries and sustainable biomanufacturing efforts.
Scientific innovation inherently involves high elements of risk and failure. However, Dr. Singh noted that true success lies in progressing despite these setbacks. He emphasized that failure is an integral part of the innovation process. Specifically, India's biotech journey is a story of growth in spite of significant adversities. Furthermore, the nation is steadily moving toward its target of a $300 billion bioeconomy by 2030. This ambitious goal relies on a strong base of scientists and entrepreneurs.
Q1: What is the current valuation of India's biotechnology sector?
As of 2025, the sector has expanded to over $195.3 billion, growing from $10 billion in 2014.
Q2: What is the government's future target for the bioeconomy?
The Indian government aims to reach a $300 billion biotechnology valuation by the year 2030.
Q3: How many biotech startups currently operate in India?
There are now more than 11,800 biotechnology startups contributing to the innovation ecosystem in India.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
India's biotech sector has surged to $195.3B, driven by BIRAC and the BioE3 policy. Discover how the nation is targeting a $300B bioeconomy by 2030....
5 months ago
A clinical comparison of extravascular and subcutaneous implantable cardioverter-defibrillators, detailing patient selection, pacing capabilities, and implantation nuances.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
